• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Targanta Therapeutics Corporation, a biopharmaceutical company, focuses on the development and commercialization of antibiotics for infections treated or acquired in hospitals and other institutional settings. It is developing Oritavancin, a novel intravenous antibiotic, for the treatment of gram-positive bacterial infections, including complicated skin and skin structure infections, and bacteremia, an infection caused by bacteria in the bloodstream.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2009-02-25 | 0 | |
|
No longer subject to file | 2009-02-25 | 0 | |
|
SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P SKYLINE VENTURE MANAGEMENT IV, LLC SKYLINE VENTURE PARTNERS III, L.P. SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND III, L.P. SKYLINE VENTURE MANAGEMENT III, LLC |
|
No longer subject to file | 2009-02-25 | 0 |
|
No longer subject to file | 2009-02-25 | 0 | |
|
No longer subject to file | 2009-02-25 | 0 | |
|
2,750,971 | 2008-11-20 | 0 | |
|
0 | 2008-08-25 | 0 | |
|
0 | 2008-08-25 | 0 | |
|
0 | 2008-06-02 | 0 | |
|
0 | 2008-06-02 | 0 | |
|
BROOKSIDE CAPITAL MANAGEMENT LLC |
|
2,771,682 | 2007-10-15 | 0 |
|
3,138,113 | 2007-10-15 | 0 | |
|
0 | 2007-10-12 | 0 | |
|
LEUCHTENBERGER MARK DIRECTOR, PRESIDENT AND CEO |
|
0 | 2007-10-12 | 0 |
|
ELDRIDGE GEORGE A CFO,TREASURER & ASST SECRETARY |
|
0 | 2007-10-12 | 0 |
|
PARR THOMAS R JR CHIEF SCIENTIFIC OFFICER |
|
0 | 2007-10-12 | 0 |
|
ETIENNE PIERRE E CHIEF DEVELOPMENT OFFICER |
|
0 | 2007-10-12 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
